ANAPTYSBIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.58 USD | +0.91% |
|
+26.57% | +24.09% |
| 16/04 | Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target | MT |
| 11/04 | Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ANAPTYSBIO, INC. | Bio Therapeutic Drugs | +0.91% | +26.57% | +24.09% | +23.63% | -63.78% | 726M |  | | |
Technical Rankings Surperformance
- Stock Market
- Equities
- ANAB Stock
- Charts AnaptysBio, Inc.
- Comparison Chart
